Written questions by Obese-Jecty.

Innovation and Technology, what estimate he has made of the potential cost to the public purse of Government funding for Wilson's disease research in financial year 2023-24; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI has funded £1,613.772 to the University of College London for a research project into antitrypsin, to form long chains of linked molecules (called "polymers") that are trapped inside liver cells. The build-up of polymers damages the cell and increases the chance of developing liver cirrhosis and liver cancer.Funding for health-related research is also available through the UK’s association with the Horizon Europe Programme, worth more than £80 billion.

Innovation and Technology, whether he has had discussions with universities on (a) their sustainability plans and (b) assessments of the sustainability of projects they (i) fund and (ii) otherwise sponsor since July 2024; and with which universities he has had such discussions.

The Department has regular discussions with businesses and universities on a range of issues, including environmental sustainability. UKRI has close engagement with the Research & Innovation sector within the UK through their Environmental Strategy, as well as the Concordat for the Environmental Sustainability of Research and Innovation Practice. The concordat aims to help the sector act responsibly to protect and promote the environment, and representation includes universities, research institutes, catapults and funding organisations. Internationally, UKRI is also part of the Heidelberg Agreement. Nine European countries collaborated on developing the agreement, through which research funders take a proactive approach to promoting sustainability in scientific research.

Innovation and Technology, what estimate he has made of the potential cost to the public purse of Government funding for Gilbert syndrome research in financial year 2023-24; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI has funded £1,613.772 to the University of College London for a research project into antitrypsin, to form long chains of linked molecules (called "polymers") that are trapped inside liver cells. The build-up of polymers damages the cell and increases the chance of developing liver cirrhosis and liver cancer.Funding for health-related research is also available through the UK’s association with the Horizon Europe Programme, worth more than £80 billion.

Innovation and Technology, whether he has had discussions with UK Research and Innovation on (a) their sustainability plans and (b) assessments of the sustainability of projects they (i) fund and (ii) otherwise sponsor since July 2024.

Ministers and officials meet regularly with UK Research and Innovation (UKRI) including its constituent councils, on a range of issues. The UKRI Environmental Sustainability Strategy 2020-2025 sets out UKRI’s ambition to protect and enhance the environment across its investments and operations, while ensuring that the research and innovation it supports stays at the cutting-edge. The UKRI Environmental Sustainability Strategy is available at: https://www.ukri.org/publications/ukri-environmental-sustainability-strategy/.As part of this Strategy, UKRI established a carbon fund, which identified and funded quick wins in their research facilities and as of April 2025 will support the implementation of a pilot scheme for carbon budgets.UKRI’s councils provide broad support for research and innovation to improve sustainability, including over £22.7 million funding over five years through the Engineering and Physical Sciences Research Council to support research that drives the transition to sustainable technologies and operations.

Innovation and Technology, what meetings (a) he, (b) his special advisers, (c) Departmental officials and (d) Ofcom have had with (i) Centre for Countering Digital Hate and (ii) Stop Funding Hate since 4 July 2024.

Ministers, special advisers, and officials have regular meetings with a range of stakeholders, details of ministerial meetings are published quarterly on the gov.uk website.Ofcom is an independent regulator, and the Department does not record Ofcom’s meetings with external organisations.

Innovation and Technology, whether (a) he, (b) special advisers and (c) officials have held meetings with (i) Centre for Countering Digital Hate and (ii) Stop Funding Hate since 4 July 2024.

Ministers, special advisers, and officials have regular meetings with a range of stakeholders, details of ministerial meetings are published quarterly on the gov.uk website.Ofcom is an independent regulator, and the Department does not record Ofcom’s meetings with external organisations.

Innovation and Technology, what discussions he has had with UK Research and Innovation on their (a) cybersecurity and (b) procedures to prevent (i) ransomware and (ii) other forms of cyber attacks since July 2024; and how many such incidents have occurred since July 2024.

Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.

Innovation and Technology, how much funding the Government provided for research into heart block in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, what the cost to the public purse was of Government funding of valvular disease research in 2023-24; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into aortic aneurysm in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into non-ST-elevation myocardial infarction in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into ST-elevation myocardial infarction in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into coronary heart disease in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into congenital heart disease in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, whether he has had discussions with universities on their (a) cybersecurity and (b) procedures to prevent (i) ransomware and (ii) other forms of cyber attacks since July 2024; and how many such incidents have occurred since July 2024.

Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.

Innovation and Technology, whether he has had discussions with the Government Office for Technology Transfer on their (a) cybersecurity and (b) procedures to prevent (i) ransomware and (ii) other forms of cyber attacks since July 2024; and how many such incidents have occurred since July 2024.

Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.

Innovation and Technology, what discussions he has had with businesses on their (a) cybersecurity and (b) procedures to prevent (i) ransomware and (ii) other forms of cyber attacks since July 2024; and how many such incidents have occurred since July 2024.

Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.

Innovation and Technology, what discussions he has had with Research England on their (a) cybersecurity and (b) procedures to prevent (i) ransomware and (ii) other forms of cyber attacks since July 2024; and how many such incidents have occurred since July 2024.

Ministers and officials meet regularly with industry stakeholders and public bodies to discuss cyber security and bolstering cyber resilience. The National Cyber Security Centre offers range of support and guidance showing businesses, agencies and government departments how to protect against cyber attacks. The Cyber Breaches Survey 2024 shows that 50% of businesses report having experienced some form of cyber security breach or attack in the last 12 months. The Government recognises the importance of strengthening the UK’s cyber resilience and protecting the digital economy to deliver growth. To address this, the Government is introducing a Cyber Security and Resilience Bill. The Bill will strengthen the UK’s cyber defences and ensure that more essential digital services than ever before are protected. On 14 January the government published a consultation on proposals to further protect businesses and public services from ransomware attacks.

Innovation and Technology, how much funding the Government provided for research into atrial fibrillation in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into Myocarditis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes. UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research. Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHR funding in FY 2023/24UKRI Funding in FY 2023/24Hypertrophic obstructive cardiomyopathyNIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24.UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24.dilated cardiomyopathy researchNIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24.The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes).valvular disease researchNIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24.The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC).myocarditisNIHR did not commit any specific funding for myocarditis research in 2023-24.UKRI did not commit any specific funding for Myocarditis research in 2023-24.heart failure researchNIHR allocated £41,442,113 research concerning heart failure research in 2023-24.The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure.congenital heart diseaseNIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC).coronary heart diseaseNIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24.The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC).ST-elevation myocardial infarctionNIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24.non-ST-elevation myocardial infarctionNIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.heart blockNIHR allocated £24,667,421 for research concerning heart block in 2023-24.UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24.atrial fibrillationNIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24.The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes).hypertensionNIHR allocated £30,552,736 for research concerning hypertension in 2023-24.The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring.aortic aneurysmNIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24.The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes)aortic dissectionNIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24.UKRI did not commit any specific funding for aortic dissection research in 2023-24.